Amylyx Hosts Investor Event to Discuss Phase 3 Avexitide Results

PUBT · 1d ago
Amylyx Hosts Investor Event to Discuss Phase 3 Avexitide Results
  • Amylyx Pharmaceuticals will host an investor event at ObesityWeek in Washington, D.C., on November 15, 2026, at 11:45 a.m. ET.
  • The in-person and virtual event will review Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
  • Trial investigators Marilyn Tan and Zeb Saeed will discuss the disease burden.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104805440) on November 04, 2026, and is solely responsible for the information contained therein.